Journal Watch
Hope for peritoneal fibrosis?
Over time, the peritoneum can become fibrous and thickened, and less able to filter the blood during PD. A new study in rats suggests that erythropoietin (EPO) may help. Rats treated with EPO had less fibrosis. Down the road, perhaps this finding will help people.
Read the abstract » | (added 2011-02-24)
Tags:
New resource for intraperitoneal drug delivery
On PD, it's not hard to inject a drug into the PD bag so it goes into the peritoneum. Which drugs are safest and most effective this way? A new article tells you the scoop.
Read the abstract » | (added 2011-02-24)
Tags:
Breast cancer drug offers hope for encapsulating peritoneal sclerosis (EPS)
Tamoxifen has been shown to improve survival in EPS--a rare, but sometimes deadly PD complication that can lead to bowel obstruction. In a study of 63 people with severe EPS, those treated with the drug had significantly better survival.
Read the abstract » | (added 2011-02-24)
Tags:
November 2006 Kidney International supplement focuses on PD
Is survival better on PD or HD? What factors predict PD success? What are best practices in PD catheter placement? Does use of biocompatible PD solution reduce peritonitis? Learn the answers to these and many other key PD questions in the November 2006 supplement of KI. (For kidney professionals who don't subscribe to Kidney International, we've compiled the links to all of the abstracts from the special supplement on PD (November 2006). You can find them below.
- Mortality studies comparing PD and HD: What do they tell us?
- French PD registry (RDPLF): Outline and main results
- PD in the US: Evaluation of outcomes in contemporary cohorts
- Selected best demonstrated practices in PD access
- Use of the embedded PD catheter: Experience and results from a North American Center
- Prevention of infectious complications in PD: Best demonstrated practices
- Microbiology and outcomes of peritonitis in North America
- Impact of new dialysis solutions on peritonitis rates
- Place of PD in the management of treatment-resistant congestive heart failure
- The role of PD in the management of treatment-resistant congestive heart failure: A European perspective
- Mitigating peritoneal membrane characteristics in modern PD therapy
- Profiles of automated PD prescriptions in the US 1997-2003
- Tidal PD: Its role in the current practice of PD
- The role of tidal PD in modern practice: A European perspective
- Glucose sparing in PD: Implications and metrics
- New insight of amino-acid based dialysis solutions
- Management of hyperlipidemia in patients on PD: Current approaches
- Structural requirements for a successful PD program
- Nosogogy: When the learner is a patient with chronic renal failure
- Patient retraining in PD: Why and when it is needed
- Patient and technique survival on peritoneal dialysis in patients with failed renal allograft: A case-control study
- Place of genotyping and phenotyping in understanding and potentially modifying outcomes in PD patients
Read the abstract » | (added 2011-02-24)
Tags:
Protect the peritoneal membrane to do PD longer
A new review article suggests replacing some glucose-based dialysate exchanges with icodextrin, resting the peritoneum, using bicarbonate or pyruvate as a buffer, and treating infections immediately as ways to help protect the peritoneal membrane.
Read the abstract » | (added 2011-02-24)
Tags:
Rat study: Celexicob reduces peritoneal fibrosis
COX-2 is involved in fibrosis and the growth of new blood vessels. Is there a way to protect the peritoneal membrane using a COX-2 inhibitor so it lasts longer for PD? Perhaps one day there will be. A new study found that rats given a substance that causes fibrosis had fewer new blood vessels and milky spots, and far less fibrosis than controls.
Read the abstract » | (added 2011-02-24)
Tags: